Current Report Filing (8-k)
August 31 2015 - 8:16AM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C.
20549
FORM 8-K
Current Report
Pursuant to Section 13 or 15(d) of
the
Securities Exchange Act of 1934
August 31, 2015
Date of Report (Date of Earliest
Event Reported)
IntelGenx Technologies Corp.
(Exact Name of Registrant as Specified in its Charter)
Delaware |
000-31187 |
870638336 |
(State or other jurisdiction of |
(Commission File |
(IRS Employer Identification |
incorporation) |
Number) |
No.) |
6425 Abrams, Ville St- Laurent, Quebec, Canada |
H4S 1X9 |
(Address of principal executive offices) |
(Zip Code) |
Registrant's telephone number, including area code: (514)
331-7440
Check the appropriate box below if the Form 8K fining is
intended to simultaneously satisfy the filing obligation of the registrant under
any of the following provisions:
[ ] Written communications pursuant to Rule 425 under the
Securities Act (17CFR230.425)
[ ] Soliciting material pursuant to Rule 14a-12 under the
Exchange Act (17CFR 240.14a -12)
[ ] Pre-commencement communications pursuant to Rule
14d-2(b) under the Exchange Act (17 CFR 240.14d -2(b))
[ ] Pre-commencement communication pursuant to Rule
13e-4(c) under the Exchange Act (17 CFR 240.13e -4(c))
Item 8.01 Other Events - News Release
IntelGenx to Present at the 17th Annual Rodman & Renshaw
Global Investment Conference
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of
1934, the Registrant has duly caused this report to be signed on its behalf by
the undersigned hereunto duly authorized.
INTELGENX TECHNOLOGIES
CORP.
Dated: August 31, 2015 |
|
By: /s/ Andre Godin |
|
|
Andre Godin |
|
|
EVP and Chief Financial Officer
|
IntelGenx to Present at the 17th Annual Rodman &
|
Renshaw Global
Investment Conference |
Saint Laurent, Quebec--(Newsfile Corp. - August 31, 2015) -
IntelGenx Corp. (TSXV: IGX) (OTCQX: IGXT) ("IntelGenx") today announced that Dr.
Horst Zerbe, Chairman, President and Chief Executive Officer, will present at
the Rodman & Renshaw Global Investment Conference on Sep 10 from
12:05 to 12:30 PM Eastern Time in the Library (2nd floor) . Also
present and available for questions will be Andre Godin, newly appointed
Executive Vice-President and Chief Financial Officer.
The Rodman & Renshaw Conference will take place at The St.
Regis Hotel in New York on September 8-10, 2015. To learn more about the
conference, please visit:
http://www.rodm.com
About IntelGenx:
IntelGenx is a drug delivery company focused on the development
of oral controlled-release products as well as novel rapidly disintegrating
delivery systems. IntelGenx uses its unique multiple layer delivery system to
provide zero-order release of active drugs in the gastrointestinal tract.
IntelGenx has also developed novel delivery technologies for the rapid
delivery of pharmaceutically active substances in the oral cavity based on its
experience with rapidly disintegrating films.
IntelGenx' development
pipeline includes products for the treatment of indications such as severe
depression, hypertension, erectile dysfunction, migraine, insomnia, CNS
indications, idiopathic pulmonary fibrosis, oncology and pain, as well as animal
health products. More information is available about the company at www.intelgenx.com.
Neither TSX Venture Exchange nor its Regulation Services
Provider (as that term is defined in policies of the TSX Venture Exchange)
accepts responsibility for the adequacy or accuracy of this release and the
OTCQX has neither approved nor disapproved the contents of this press
release.
INVESTOR CONTACT:
COCKRELL GROUP
Rich Cockrell
877-889-1972
investorrelations@thecockrellgroup.com
cockrellgroup.com
COMPANY CONTACT:
Andre Godin
EVP and Chief Financial Officer
IntelGenx Technologies Corp.
T: +1 514-331-7440
andre@intelgenx.com
www.intelgenx.com
IntelGenx Technologies (CE) (USOTC:IGXT)
Historical Stock Chart
From Aug 2024 to Sep 2024
IntelGenx Technologies (CE) (USOTC:IGXT)
Historical Stock Chart
From Sep 2023 to Sep 2024